Frontiers in nutrition · 2026
Polysaccharides from Elsholtzia rugulosa: structural characteristics and treating functional dyspepsia via gut microbiome in conjunction with targeting the PI3K/Akt/cGMP-PKG pathways.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ai Run, Xu Xue-Ying, Khan Afsar, Geng Jia-Mei, Tan Wen-Hong, Wang Yi-Fen, Liu Lu
Аннотация
BACKGROUND: Functional dyspepsia (FD) is a common gastrointestinal disorder characterized by symptoms such as epigastric pain, bloating, and nausea. Current treatments have limited efficacy and significant side effects. Elsholtzia rugulosa, a traditional medicinal plant, is used to treat gastrointestinal disorders, and its polysaccharides (ERP) may offer therapeutic potential for FD.
OBJECTIVE: This study aimed to characterize the structural properties of Elsholtzia rugulosa polysaccharides (ERP) and explore their mechanism in treating FD.
MATERIALS AND METHODS: Neutral ERP-N and acidic ERP-A were isolated from Elsholtzia rugulosa. Their structural features were analyzed, and FD rats were treated with ERP. Gastric pathology, gut microbiota, and the PI3K/Akt/cGMP-PKG pathway were evaluated. RAW264.7 cells were used to assess ERP's immunomodulatory effects.
RESULTS: Structural Analysis: ERP-N (13,415 Da) and ERP-A (3,691 Da) exhibited distinct monosaccharide compositions and linkages. Therapeutic Effects: ERP improved FD symptoms, reduced inflammation, regulated gut microbiota, and activated the PI3K/Akt/cGMP-PKG pathway in rats. Immunomodulatory Activity: ERP-N promoted the secretion of nitric oxide (NO), TNF-α, and IL-6 in RAW264.7 cells, demonstrating immunomodulatory effects.
CONCLUSION: ERP may alleviate FD in association with gut microbiota modulation and changes in the PI3K/Akt/cGMP-PKG-related pathway. ERP-N also exhibits immunomodulatory activity, supporting the traditional use of Elsholtzia rugulosa in gastrointestinal health and offering potential for FD therapy development.
OBJECTIVE: This study aimed to characterize the structural properties of Elsholtzia rugulosa polysaccharides (ERP) and explore their mechanism in treating FD.
MATERIALS AND METHODS: Neutral ERP-N and acidic ERP-A were isolated from Elsholtzia rugulosa. Their structural features were analyzed, and FD rats were treated with ERP. Gastric pathology, gut microbiota, and the PI3K/Akt/cGMP-PKG pathway were evaluated. RAW264.7 cells were used to assess ERP's immunomodulatory effects.
RESULTS: Structural Analysis: ERP-N (13,415 Da) and ERP-A (3,691 Da) exhibited distinct monosaccharide compositions and linkages. Therapeutic Effects: ERP improved FD symptoms, reduced inflammation, regulated gut microbiota, and activated the PI3K/Akt/cGMP-PKG pathway in rats. Immunomodulatory Activity: ERP-N promoted the secretion of nitric oxide (NO), TNF-α, and IL-6 in RAW264.7 cells, demonstrating immunomodulatory effects.
CONCLUSION: ERP may alleviate FD in association with gut microbiota modulation and changes in the PI3K/Akt/cGMP-PKG-related pathway. ERP-N also exhibits immunomodulatory activity, supporting the traditional use of Elsholtzia rugulosa in gastrointestinal health and offering potential for FD therapy development.